"In 2006, we expect to launch two to three products from Pfizer's global product portfolio as a part of our realignment of business in India keeping in tune with global strategy," Kewal Handa, managing director, Pfizer Ltd said while unveiling its erectile dysfunction pill 'Viagra'.
He, however, declined to comment on the therapeutic areas of the proposed product launches. Asked if the new launches in the next year would be patented products, he replied in the negative and said, "We are looking at bringing a patented product by 2007."
Handa also said the company was looking at a double digit growth in India in the fiscal 2006-07. "The industry's growth has slowed down to 6-7 per cent but we expect to maintain a healthy double digit growth from the existing portfolios and new launches," he said.
The company is confident of raking in significant revenue from Viagra. "The overall erectile dysfunction drugs market in India is estimated to be about Rs 70-100 crore (Rs 700 million to Rs 1 billion) and we are aiming at capturing 10-15 per cent of the market in two years time," K G Ananthakrishnan, senior director, Pfizer Ltd said.
Pfizer is also confident that its top grosser brands like Becosule and Corex, which had a turnover of Rs 70 crore and about Rs 90 crore (Rs 900 million) respectively during the year 2005, would continue to do well, he said.